Null Anticarcinogenic Effect of Silymarin on Diethylnitrosamine-induced Hepatocarcinogenesis in Rats

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2013 Dec 19

PMID 24348760

Citations 11

Authors

Ryu Imamoto

Jun-Ichi Okano

Shintaro Sawada

Yuki Fujise

Ryo Abe

Yoshikazu Murawaki

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the anticarcinogenic effects of silymarin in diethylnitrosamine (DEN)-induced hepatocarcinogenic rat models. Severe and mild models of hepatocellular carcinoma (HCC) were generated by the intraperitoneal administration of 40 mg/kg DEN once a week for 18 weeks and 100 mg/kg DEN every 2 weeks for 6 weeks in male Wistar rats, respectively. In the severe and mild models of HCC, the rats were treated with 0.1 and 0.5% silymarin for 18 weeks and with 0.1% silymarin for 5 weeks, respectively. Serum transaminase levels were not significantly decreased by the silymarin treatment in either model. Macroscopic and microscopic features indicated that the silymarin-containing formulations did not significantly inhibit the hepatic tumor formation induced by DEN. Furthermore, immunohistochemical and western blot analyses demonstrated that the expression levels of proliferating cell nuclear antigen and glutathione -transferase P, which are hepatocarcinogenic markers, were not significantly modified by the silymarin treatment. These results indicate that silymarin may not be considered as a candidate agent against hepatocarcinogenesis.

Citing Articles

Protective effects of L. extract against -diethylnitrosamine-induced hepatocellular carcinoma in male Wistar rats through antioxidative, anti-inflammatory, mitochondrial apoptosis and PI3K/Akt/mTOR signaling pathways.

Wang Z, Jiang X, Zhang L, Chen H Food Sci Nutr. 2023; 11(8):4756-4772.

PMID: 37576045 PMC: 10420783. DOI: 10.1002/fsn3.3455.

Silymarin inhibits the progression of Ehrlich solid tumor via targeting molecular pathways of cell death, proliferation, angiogenesis, and metastasis in female mice.

Amer M, Amer M, Othman A, Elsayed D, El-Missiry M, Ammar O Mol Biol Rep. 2022; 49(6):4659-4671.

PMID: 35305227 DOI: 10.1007/s11033-022-07315-2.

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Koltai T, Fliegel L J Evid Based Integr Med. 2022; 27:2515690X211068826.

PMID: 35018864 PMC: 8814827. DOI: 10.1177/2515690X211068826.

Circulating MicroRNAs in Gastrointestinal Cancer.

Ohtsuka M, Iwamoto K, Naito A, Imasato M, Hyuga S, Nakahara Y Cancers (Basel). 2021; 13(13).

PMID: 34283058 PMC: 8267753. DOI: 10.3390/cancers13133348.

Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma.

Cao X, Yang Q, Yu Q Open Forum Infect Dis. 2020; 7(12):ofaa498.

PMID: 33364257 PMC: 7749721. DOI: 10.1093/ofid/ofaa498.

References

Okano J, Fujise Y, Abe R, Imamoto R, Murawaki Y . Chemoprevention against hepatocellular carcinoma. Clin J Gastroenterol. 2015; 4(4):185-197. DOI: 10.1007/s12328-011-0227-8. View

Tyagi A, Raina K, Singh R, Gu M, Agarwal C, Harrison G . Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther. 2007; 6(12 Pt 1):3248-55. DOI: 10.1158/1535-7163.MCT-07-2006. View

Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S . Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis. 1999; 20(1):59-63. DOI: 10.1093/carcin/20.1.59. View

Bosch F, Ribes J, Borras J . Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19(3):271-85. DOI: 10.1055/s-2007-1007117. View

Ramakrishnan G, Augustine T, Jagan S, Vinodhkumar R, Devaki T . Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol. 2007; 29(1):39-44. View

Freedman N, Curto T, Morishima C, Seeff L, Goodman Z, Wright E . Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther. 2010; 33(1):127-37. PMC: 3490214. DOI: 10.1111/j.1365-2036.2010.04503.x. View

Alenzi F, El-Nashar E, Al-Ghamdi S, Abbas M, Hamad A, El-Saeed O . Original Article: Investigation of Bcl-2 and PCNA in Hepatocellular Carcinoma: Relation to Chronic HCV. J Egypt Natl Canc Inst. 2011; 22(1):87-94. View

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

Hong W, Lippman S . Cancer chemoprevention. J Natl Cancer Inst Monogr. 1995; (17):49-53. View

10.

Chuang S, Kuo M, Hsu C, Chen C, Lin J, Lai G . Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 2000; 21(2):331-5. DOI: 10.1093/carcin/21.2.331. View

11.

Deep G, Oberlies N, Kroll D, Agarwal R . Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008; 123(1):41-50. DOI: 10.1002/ijc.23485. View

12.

Varghese L, Agarwal C, Tyagi A, Singh R, Agarwal R . Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005; 11(23):8441-8. DOI: 10.1158/1078-0432.CCR-05-1646. View

13.

Lee J, Abou-Alfa G . An update on clinical trials in the treatment of advanced hepatocellular carcinoma. J Clin Gastroenterol. 2013; 47 Suppl:S16-9. DOI: 10.1097/MCG.0b013e31827d77a2. View

14.

Abe R, Okano J, Imamoto R, Fujise Y, Koda M, Murawaki Y . [Evaluation of the surveillance program for hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi. 2012; 109(5):741-50. View

15.

Zhang Y, Tang L . Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007; 28(9):1343-54. DOI: 10.1111/j.1745-7254.2007.00679.x. View

16.

Feher J, Lengyel G . Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2011; 13(1):210-7. DOI: 10.2174/138920112798868818. View

17.

Avila M, Berasain C, Sangro B, Prieto J . New therapies for hepatocellular carcinoma. Oncogene. 2006; 25(27):3866-84. DOI: 10.1038/sj.onc.1209550. View

18.

El-Shahat M, El-Abd S, Alkafafy M, El-Khatib G . Potential chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis in rats: myrrh (Commiphora molmol) vs. turmeric (Curcuma longa). Acta Histochem. 2011; 114(5):421-8. DOI: 10.1016/j.acthis.2011.08.002. View

19.

Farazi P, DePinho R . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6(9):674-87. DOI: 10.1038/nrc1934. View

20.

Verna L, Whysner J, Williams G . N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther. 1996; 71(1-2):57-81. DOI: 10.1016/0163-7258(96)00062-9. View